Sign up Australia
Proactive Investors - Run By Investors For Investors

Rhinomed takes its nasal breathing product into the Taiwanese market

“Mute” is an over-the-counter product to enable snorers to breathe more easily.
Rhinomed takes its nasal breathing product into the Taiwanese market
The product is designed to fit the natural anatomy of the nose

Rhinomed Ltd (ASX:RNO) has signed a distribution agreement with Brojaw Inc., to begin distributing its snoring and nasal breathing product Mute into the Taiwanese market.

The company’s shares were last trading circa 8% higher intra-day, at $0.205.

Mute is an over-the-counter product to enable snorers to breathe more easily through their nose and keep their mouth closed during sleep. In turn, this reduces vibration in the airways that causes snoring.

The product is designed to fit the natural anatomy of the nose and it is adjustable so the user can control the level of dilation and airflow.

The new non-exclusive agreement will see Brojaw distribute Mute to ear, nose and throat (ENT) clinics, sleep doctors, sleep centres, medical centres and sleep clinics in Taiwan.

This will then be followed by distribution into drug stores / pharmacies. An initial purchase order has been received.

This agreement follows the recent approval of Mute by the Taiwanese Food and Drug Administration (TFDA) as a class 1 medical device.

In July, Rhinomed received purchase orders from the U.S. pharmacy giant Walgreens for Mute to be sold in circa 4,300 pharmacy/drugstores throughout the U.S.

This 5 fold increase in U.S. distribution has occurred 12 months after the start of the initial trial that began in 107 Duane Reade stores and 891 Walgreens stores in May 2016.





Register here to be notified of future RNO Company articles
View full RNO profile View Profile

Rhinomed Ltd Timeline

Newswire
March 13 2017
Newswire
September 16 2015

Related Articles

1504120610_biotechLatest.jpg
September 01 2017
The company is poised for a milestone-rich period over the next year or so
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use